Clik here to view.
Inocras Unveils Breakthrough Study, Proving Target-Enhanced Whole-Genome...
SAN DIEGO Inocras, an industry leader in whole genome sequencing and bioinformatics, released a new study highlighting the clinical validation of its CancerVision Target-Enhanced Whole-Genome...
View ArticleClik here to view.
MEDiC Life Sciences Announces Collaboration with Hanmi Pharmaceutical on...
MOUNTAIN VIEW, Calif. MEDiC Life Sciences (“MEDiC”), a Silicon Valley biotech startup, today announced that it has entered a research collaboration with Hanmi Pharmaceutical (“Hanmi”), a leading...
View ArticleClik here to view.
JCR Pharmaceuticals to Present at the European Society of Gene and Cell...
HYOGO, Japan JCR Pharmaceuticals Co., Ltd. (TSE 4552; Chairman and President: Shin Ashida; “JCR”) announced today that it will present preclinical data from its proprietary J-Brain Cargo®-applied...
View ArticleClik here to view.
藤田医科大学羽田クリニックにおいてBostonGene 社が開発したTumor Portrait™検査を導入。がん患者さんの包括的ゲノム検査として開始します。
東京 & WALTHAM, Mass. （ビジネスワイヤ） — AIによる分子免疫プロファイリングソリューションのリーディングカンパニーであるBostonGeneは、藤田医科大学羽田クリニックにてBostonGene社開発の Tumor Portrait™を用いたがんゲノムプロファイリング検査を開始します。...
View ArticleClik here to view.
Fujita Health University and BostonGene Expand Access to Genomic Cancer...
TOKYO & WALTHAM, Mass. Fujita Health University and BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, announced today that the Fujita Health University Haneda...
View ArticleClik here to view.
JCR Pharmaceuticals Presents Preclinical Gene Therapy Research at the...
HYOGO, Japan JCR Pharmaceuticals Co., Ltd. (TSE 4552; Chairman and President: Shin Ashida; “JCR”) announced today that the Company presented preclinical data from its novel adeno-associated virus...
View ArticleClik here to view.
Clik here to view.
Modalis Therapeutics has received an Orphan Drug Designation from the U.S....
TOKYO & WALTHAM, Mass. Modalis Therapeutics Corporation (Tokyo Stock Exchange: 4883, CEO: Haru Morita), a leading company pioneering treatments for rare genetic diseases using its proprietary...
View Article